Cell Therapeutics, Inc. (CTI) Announces Presentations at AmericanSociety of Clinical Oncology (ASCO) Annual Meeting
SEATTLE, May 27, 2008 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) today announced that the following presentations will be made on its product Zevalin(R) (Ibritumomab Tiuxetan) and its development product OPAXIO(TM) (paclitaxel poliglumex, formerly XYOTAX(TM)) at the 44th American Society of Clinical Oncology (ASCO) Annual Meeting, May 30 through June 3, 2008, in Chicago.
Date Time Poster # Title (Abstract#) Sat., 8:00 AM 47D(8565) Phase I trial of yttrium 90 May 31 poster ibritumomab tiuxetan (90Y-RIT) with autologous stem cell transplantation (ASCT) in patients with relapsed or refractory B-cell non- Hodgkin's lymphoma (NHL) Sat., 8:00 AM 56E(8615) Yttrium-90 ibritumomab May 31 poster tiuxetan combined with high- dose BEAM chemotherapy and autologous stem cell transplantation for relapsed/refractory B-cell non-Hodgkin's lymphoma Sun., 2:00 PM 20D(3075) Retrospective study of RIT June 1 poster (radiolabelled immunotherapy) with 90Y-IT (90Y-ibritumomab tiuxetan) in relapsing FL (follicular lymphoma) after autologous (BM) bone marrow transplant (ABMT) Mon., 2:00 PM 32A(1063) Phase II trial of paclitaxel June 2 poster poliglumex (PPX) with capecitabine (C) for metastatic breast cancer (MBC).
For more information about the ASCO annual meeting, please refer to the conference Web site at http://www.asco.org/.
Zevalin(R) (Ibritumomab Tiuxetan) is a form of cancer therapy called radioimmunotherapy and is indicated as part of the Zevalin therapeutic regimen for treatment of relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma, including patients with rituximab refractory follicular NHL. It was approved by the FDA in February of 2002 as the first radioimmunotherapeutic agent for the treatment of NHL.
Rare deaths associated with an infusion reaction symptom complex have occurred within 24 hours of rituximab infusions. Yttrium-90 Zevalin administration results in severe and prolonged cytopenias in most patients. Severe cutaneous and mucocutaneous reactions have been reported. The most serious adverse reactions of the Zevalin therapeutic regimen were primarily hematologic, including neutropenia, thrombocytopenia, and anemia. Infusion- related toxicities were associated with pre-administration of rituximab. The risk of hematologic toxicity correlated with the degree of bone marrow involvement prior to Zevalin therapy. Myelodysplasia or acute myelogenous leukemia was observed in 2 percent of patients (8 to 34 months after treatment). Zevalin should only be used by health care professionals qualified by training and experience in the safe use of radionuclides.
Patients and healthcare professionals can visit http://www.zevalin.com for more information.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products. For additional information, please visit http://www.CellTherapeutics.com.
Media Contact: Dan Eramian T: 206.272.4343 C: 206.854.1200 Investors Contact: Leah Grant T: 206.282.7100 F: 206.272.4434 E: email@example.com Medical Information Contact: T: 800.715.0944 E: firstname.lastname@example.org
CONTACT: Media, Dan Eramian, +1-206-272-4343, cell, +1-206-854-1200,, or Investors, Leah Grant, +1-206-282-7100, fax,+1-206-272-4434, , or Medical Information,1-800-715-0944, , all of Cell Therapeutics, Inc. email@example.com firstname.lastname@example.org email@example.com
Web site: http://www.celltherapeutics.com/
Ticker Symbol: (NASDAQ-NMS:CTIC)
Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: May 2008